Strengthening Leadership in Adult Immunization
Sanofi has completed its acquisition of Dynavax Technologies Corporation (Dynavax), thereby strengthening its position in adult immunization. Through this acquisition, Sanofi adds Dynavax’s adult hepatitis B vaccine, HEPLISAV-B, to its portfolio. HEPLISAV-B is currently marketed in the United States and stands out for its two-dose regimen administered over one month.
In addition, Sanofi acquires Dynavax’s shingles vaccine candidate, Z-1018, which is currently undergoing Phase 1/2 clinical studies, along with other vaccine pipeline assets. By integrating these products and candidates, Sanofi combines Dynavax’s innovative vaccines with its own global commercial reach, development expertise, and large-scale manufacturing capabilities.
Completion of Tender Offer
As per the Sanofi Press release, the tender offer for all outstanding shares of Dynavax common stock, with a par value of $0.001 per share, expired shortly after 11:59 p.m. EST on February 9, 2026. All required conditions, including the minimum tender condition, were satisfied. Consequently, on February 10, 2026, Sanofi accepted for payment all shares that were validly tendered and not withdrawn and will promptly complete the corresponding payments.
Merger Finalizes Transaction
Following the acceptance of tendered shares, Sanofi finalized the acquisition by merging a wholly owned subsidiary into Dynavax under Section 251(h) of the General Corporation Law of the State of Delaware. As a result, Dynavax continues as the surviving corporation and now operates as an indirect, wholly owned subsidiary of Sanofi.
Furthermore, the merger converted all remaining Dynavax shares that were not validly tendered into the right to receive $15.50 per share in cash, without interest and subject to applicable withholding taxes. This amount matches the consideration offered in the tender process.